Navigation Links
GPhA Praises President Obama's Support for Safe and Affordable Biogenerics as Critical Solution to America's Ailing Health Care System
Date:2/26/2009

ARLINGTON, Va., Feb. 26 /PRNewswire/ -- The Generic Pharmaceutical Association (GPhA) today applauded President Obama's budget proposal for including a workable approval pathway for biogenerics that will substantially reduce health care costs by increasing access to quality care at affordable prices. The President's budget proposal would ensure that this process mirrors the proven Hatch-Waxman market exclusivity model, by ensuring that brand companies cannot extend exclusivity using "ever-greening."

"For patients across the country suffering from cancer, diabetes and other diseases, the support stated by President Obama today for a workable biogenerics approval pathway is lifesaving news. With countless patients struggling to pay the high costs of brand biopharmaceuticals, an approval pathway for safe, effective and affordable biogeneric medicines that provides access sooner rather than later is desperately needed. GPhA applauds the President's budget message specifically stating that a workable scientific, regulatory and legal pathway with exclusivity provisions consistent with the Hatch-Waxman model must be enacted. The exclusivity provisions of Hatch-Waxman have been a successful model, fostering innovation and competition while saving hundreds of billions of dollars, and this same success can be achieved with biogenerics," stated GPhA President and CEO Kathleen Jaeger.

"GPhA, AARP and numerous employers, labor, consumer and other organizations have consistently called for the creation of a workable approval pathway for biogenerics. We are pleased that the budget proposal specifically calls for: (1) creation of such a pathway; (2) biologic market exclusivity incentives consistent with 'the principles in the Hatch-Waxman law for traditional products;' and (3)'brand biologic manufacturers would be prohibited from reformulating existing products into new products to restart the exclusivity process, a process known as ever-greening.' The President clearly recognizes that unprecedented and unwarranted ever-greening provisions will only delay patient access to needed medicines and do nothing to lower health care costs.

"Controlling health care costs is a key component of the President's health care reform agenda and a critical step to putting our economy back on track. It is anticipated that by 2012, nearly half of all prescription drugs in the United States will be biologic products. As our elected officials grapple with serious economic and health care challenges, increasing access to generic and biogeneric medicines will significantly reduce health care costs and strengthen the availability of high quality health care," Jaeger concluded.

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 67% of the total prescriptions dispensed in the United States, but only 20% of all dollars spent on prescription drugs. For more information about the industry, visit www.gphaonline.org.


'/>"/>
SOURCE The Generic Pharmaceutical Association (GPhA)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AHIP Praises Bipartisan Senate Vote on Mental Health Parity
2. Union President Praises Hillary Clintons Health Plan
3. AIDS Action Council Praises Release of Latest State of AIDS in Black America Report
4. Lung Cancer Alliance Praises Congressional Call for Increased Commitment to Fund Lung Cancer Research
5. Bishops Conference Praises Senate Introduction of Pregnant Women Support Act
6. American Life League Praises Colorado Efforts to Stop Planned Parenthood Abortion Facility
7. Alliance for Quality Nursing Home Care Praises CMS Release of Updated Special Focus Facilities (SFF) List
8. Blunt Praises Presidents Plan to Save Medicare
9. FRC Action Praises John McCains Pro-Life Comments
10. Consumer Watchdog Praises CA HMO Regulators Promise to Reinstate Health Coverage for Wrongfully Cancelled Patients; Cautions That All Health Costs During Gap Must be Covered
11. USCCB Official Praises Senate Passage of Genetic Information Nondiscrimination Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... IN (PRWEB) , ... May 03, 2016 , ... ... benefits advisory organization, announces Benefits Alliance Insurance Services as the latest addition to ... Southern California-based Firm comprised of Partners Wayne Blasman, David Styles, and Paul Vincent. ...
(Date:5/3/2016)... ... May 03, 2016 , ... For the sixth consecutive year, ... Technology (ICT) companies in the annual Branham300 listing. For 23 years, the Branhan300 ... ranked by revenue. , “We are honored to be on the Branham300 ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Dr. Poneh ... on cosmetic dental treatments to both new and existing patients. Cosmetic dentistry allows patients ... for patients who have healthy smiles with some minor or more serious cosmetic flaws. ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... availability of the latest release of DocAve 6 Service Pack (SP) 7, ... organizations migrate to SharePoint 2016 and take advantage of the platform’s latest features ...
(Date:5/3/2016)... , ... May 03, 2016 ... ... of Microsoft secure remote access connectivity solutions, today announced the new SecureAccess ... Microsoft DirectAccess. The new Celestix SecureAccess release will enable organizations to get ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... -- According to market research "Global Magnetic ... Demand Forecast to 2022 - Industry Insights by Architecture ... High Field, Low to Mid Field, and Ultra High ... Vascular, Breast, Pelvic and Abdomen, Cardiac, and Other)" P&S ... was valued at $5,351.7 million in 2015, and it ...
(Date:5/3/2016)... , May 3, 2016 ... Research Report provides a basic overview of the ... post which the surgical mesh report explores into ... Complete report on Surgical Mesh market ... and 98 tables and figures is available at ...
(Date:5/2/2016)... 2016  Deerfield announced today it led the ... Inc. Graybug Vision is an early stage pharmaceutical ... care for ocular diseases including wet age-related macular ... first developed at Johns Hopkins University and has ... Graybug Vision is developing ophthalmology products ...
Breaking Medicine Technology: